NCT01918982

Brief Summary

We aimed to see if aortic aneurysms could be followed-up by circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood level.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Oct 2013

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 6, 2013

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 8, 2013

Completed
2 months until next milestone

Study Start

First participant enrolled

October 1, 2013

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2016

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2016

Completed
Last Updated

August 8, 2013

Status Verified

August 1, 2013

Enrollment Period

2.3 years

First QC Date

August 6, 2013

Last Update Submit

August 7, 2013

Conditions

- Aortic Aneurysm

Keywords

Aortic aneurysmcirculating endothelial progenitor cells

Outcome Measures

Primary Outcomes (1)

  • Circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood concentration

    Patients are followed for 2 years

    2 years

Study Arms (1)

Aortic aneurysm

Patients with aortic aneurysm \>30mm and \< 50mm

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with aortic aneurysm

You may qualify if:

  • Aortic aneurysm size \>30mm and \> 50mm

You may not qualify if:

  • Infectious disease
  • Inflammatory disease
  • Liver insuffisency
  • Cancer evolutive
  • Pregnant women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Parietti E, Pallandre JR, Deschaseaux F, Aupecle B, Durst C, Kantelip JP, Chocron S, Davani S. Presence of circulating endothelial progenitor cells and levels of stromal-derived factor-1alpha are associated with ascending aorta aneurysm size. Eur J Cardiothorac Surg. 2011 Jul;40(1):e6-12. doi: 10.1016/j.ejcts.2011.02.065. Epub 2011 Apr 9.

    PMID: 21481600BACKGROUND

MeSH Terms

Conditions

Aortic Aneurysm

Condition Hierarchy (Ancestors)

AneurysmVascular DiseasesCardiovascular DiseasesAortic Diseases

Study Officials

  • Sidney Chocron, MD, PhD

    Université de Franche-comté. France

    PRINCIPAL INVESTIGATOR

  • Andrea Perrotti, MD

    Université de Franche-Comté. France

    PRINCIPAL INVESTIGATOR

  • Simon Rinckenbach, MD, PhD

    Université de Franche-Comté. France

    PRINCIPAL INVESTIGATOR

  • Siamak Davani, MD, PhD

    Université de Franche-Comté. France

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Sidney Chocron

CONTACT

+33381533121sidney.chocron@univ-fcomte.fr

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, PhD

Study Record Dates

First Submitted

August 6, 2013

First Posted

August 8, 2013

Study Start

October 1, 2013

Primary Completion

February 1, 2016

Study Completion

May 1, 2016

Last Updated

August 8, 2013

Record last verified: 2013-08